Key result
Higher TAPSE/sPAP ratio is linked to ~78% greater odds of achieving low-risk status in PAH.
Why the study?
Does the TAPSE/sPAP ratio improve risk assessment and survival prediction in patients with pulmonary arterial hypertension compared to standard risk scores alone?
Cohort (n=931)
Yes
Does the TAPSE/sPAP ratio improve risk assessment and survival prediction in patients with pulmonary arterial hypertension compared to standard risk scores alone?
The TAPSE/sPAP ratio improves the prognostic accuracy of established risk assessment scores (ESC/ERS and REVEAL 2.0) in patients with pulmonary arterial hypertension, particularly in intermediate risk strata.
BACKGROUND: Right ventricular functional adaptation to afterload is a major determinant of outcome in pulmonary arterial hypertension (PAH). We aimed to investigate if right ventricular-PA coupling evaluated by the ratio of tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary artery pressure (sPAP) improves risk assessment scores for survival prediction. METHODS: A total of 677 consecutive patients with PAH (55% idiopathic) were prospectively enrolled with follow-up clinical, right heart catheterization, and echocardiographic evaluations within 12 months (interquartile range, 180–344 days) after initiation of targeted therapies in 11 Italian centers. European Society of Cardiology/European Respiratory Society guidelines-derived risk scores and REVEAL 2.0 (US Registry to Evaluate Early and Long-Term PAH Disease Management 2.0) risk scores were collected at baseline and follow-up. 254 consecutive patients with PAH retrospectively enrolled in a German reference center served as a validation cohort. RESULTS: A low-risk status at a median of 3.7 years (interquartile range, 1.2–6.8) follow-up was significantly associated with each unit (0.1 mm/mm Hg) increase in TAPSE/sPAP under targeted therapies (European Society of Cardiology/European Respiratory Society score: odds ratio, 1.78; P ≤0.001; REVEAL 2.0 score: odds ratio, 1.43; P ≤0.001). At follow-up, the TAPSE/sPAP ratio increased the prognostic information of each risk stratum of the European Society of Cardiology/European Respiratory Society risk score, except the highest risk stratum, with 0.5 mm/mm Hg, 0.35 mm/mm Hg, and 0.30 mm/mm Hg, from the lowest to the intermediate-high risk score, identified as the best cutoff value. TAPSE/sPAP ratio increased the prognostic information of the REVEAL 2.0 score at follow-up, with 0.35 mm/mm Hg identified as the best cutoff value to discriminate within a score of 5 to 8, with no added value for scores <5 and >8. These results were confirmed in the validation cohort. CONCLUSIONS: Assessment of right ventricular-PA coupling by the TAPSE/sPAP ratio in PAH improves risk assessment scores except in the lowest or most advanced stage of the disease
No takes yet. Share an insight, caveat, or question.
Badagliacca et al. (2025) conducted a cohort in Pulmonary arterial hypertension (PAH) (n=931). TAPSE/sPAP ratio was evaluated on Low-risk status at follow-up (European Society of Cardiology/European Respiratory Society score) (OR 1.78, p=≤0.001). Each 0.1 mm/mm Hg increase in the TAPSE/sPAP ratio was significantly associated with achieving a low-risk status at follow-up (OR 1.78, P≤0.001), improving prognostic risk assessment in PAH.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: